Late gadolinium enhancement on cardiac magnetic resonance images predicts reverse remodeling in patients with nonischemic cardiomyopathy treated with carvedilol

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1588-1589

  Kida, Keisuke ^a   Yoneyama, Kihei ^a   Kobayashi, Yasuyuki ^a   Takano, Makoto ^a   Akashi, Yoshihiro J ^a   Miyake, Fumihiko ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Beta blocker; Echocardiography; Ejection fraction; Myocardial fibrosis

Indexed keywords

CARVEDILOL; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE;

ANGIOCARDIOGRAPHY; CARDIOVASCULAR MAGNETIC RESONANCE; CONGESTIVE HEART FAILURE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOCARDIOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; LEFT VENTRICULAR REVERSE REMODELING; LETTER; MAJOR CLINICAL STUDY; NONISCHEMIC CARDIOMYOPATHY; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

BETA BLOCKER; ECHOCARDIOGRAPHY; EJECTION FRACTION; MYOCARDIAL FIBROSIS;

ADULT; AGED; CARBAZOLES; CARDIOMYOPATHIES; FEMALE; GADOLINIUM; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPANOLAMINES; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; VENTRICULAR REMODELING;

EID: 84885301121     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.01.043     Document Type: Article

References (9)

1. Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol Improves left ventricular function and reduces cardiovascular hospitalization In Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004;147(2):324-30.
2. Wu KC,Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis In nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51(25):2414-21.
3. Cho JR, Park S, Choi BW, et al. Delayed enhancement magnetic resonance Imaging Is a significant prognostic factor In patients with non-ischemic cardiomyopathy. Circ J 2010;74(3):476-83.
4. Schalla S, Bekkers SC, Dennert R, et al. Replacement and reactivemyocardial fibrosis In Idiopathic dilated cardiomyopathy: comparison of magnetic resonance Imaging with right ventricular biopsy. Eur J Heart Fail 2010;12(3):227-31.
5. Park S, Choi BW, Rim SJ, et al. Delayed hyperenhancement magnetic resonance Imaging Is useful In predicting functional recovery of nonischemic left ventricular systolic dysfunction. J Card Fail 2006;12(2):93-9.
6. Barbati G, Merlo M, Marocco P, et al. Relative survival In dilated cardiomyopathy: a stratification study of long-termoutcome to evaluate life Insurance cover. J InsurMed 2009;41(2):117-26.
7. Lehrke S, Lossnitzer D, Schob M, et al. Use of cardiovascular magnetic resonance for risk stratification In chronic heart failure: prognostic value of late gadolinium enhancement In patients with non-ischaemic dilated cardiomyopathy. Heart 2011;97(9):727-32.
8. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis In dilated cardiomyopathy. J Am Coll Cardiol 2006;48(10):1977-85.
9. Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling In patients with heart failure undergoing beta-blocker therapy. Circulation 2003;108(16):1945-53.